MicroPort Scientific Corporation's Subsidiary Endovastec™ Achieves First Commercial Use of Cratos™ in Hungary
Reuters
Sep 16
MicroPort Scientific Corporation's Subsidiary Endovastec™ Achieves First Commercial Use of Cratos™ in Hungary
Endovastec™, a subsidiary of MicroPort Scientific Corporation, recently completed the first commercial use of its Cratos™ Thoracic Branch Stent Graft System in Hungary. The procedure was successfully performed at the University of Pecs Medical School. Cratos™ is an evolution of the Castor™ system and is approved for clinical use in Europe.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MicroPort Scientific Corporation published the original content used to generate this news brief on September 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.